EyePoint Pharmaceuticals and Rallybio have entered into a research collaboration to investigate sustained delivery of Rallybio’s complement C5 inhibitor using EyePoint’s Durasert technology.
“Rallybio’s C5 inhibitor is an affibody with high affinity to its target,” Jay S. Duker, MD, president and chief operating officer of EyePoint, told Healio/OSN. “The successful implementation of this molecule into EyePoint’s Durasert technology could allow much less frequent dosing schedules with potentially superior results due to the zero-order kinetics that is